AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.
The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.
Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Country | United States |
IPO Date | Jun 19, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 110 |
CEO | Dr. Edward M. Kaye M.D., Ph.D. |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts United States | |
Website | https://www.stoketherapeutics.com |
Stock Details
Ticker Symbol | STOK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001623526 |
CUSIP Number | 86150R107 |
ISIN Number | US86150R1077 |
Employer ID | 47-1144582 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Edward M. Kaye M.D., Ph.D. | Chief Executive Officer & Director |
Thomas Edward Leggett | Chief Financial Officer |
Dawn Kalmar | Chief Communications Officer |
Dr. Adrian R. Krainer Ph.D. | Co-Founder & Independent Director |
Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
Eric Rojas | Head of Investor Relations |
Isabel Aznarez Ph.D. | Co-Founder, Head of Research & Senior Vice President |
Joan Wood | Chief Human Resources Officer |
Jonathan Allan J.D. | Corporate Secretary & General Counsel |
Shamim Ruff M.S. | Senior Vice President of Quality & Chief Regulatory Affairs Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 07, 2025 | 8-K | Current Report |
Jan 02, 2025 | 4 | Filing |
Dec 27, 2024 | SCHEDULE 13D/A | [Amend] Filing |
Dec 27, 2024 | 4 | Filing |
Dec 11, 2024 | 4 | Filing |
Dec 11, 2024 | 4 | Filing |
Dec 11, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |